Trial Outcomes & Findings for A Pilot Study on Diurnal Variation (NCT NCT01806051)

NCT ID: NCT01806051

Last Updated: 2016-04-20

Results Overview

To evaluate the patterns of change in plasma Phe and tyrosine levels between the Baseline visit and 4 week visit for each arm.

Recruitment status

TERMINATED

Study phase

NA

Target enrollment

6 participants

Primary outcome timeframe

Baseline and 4 weeks

Results posted on

2016-04-20

Participant Flow

No data was collected because all of the participants who consented to participate in the study withdrew due to the procedural challenges of remaining in the study (e.g. the PM blood draws were too disruptive).

Participant milestones

Participant milestones
Measure
All Participants
Participants signed the consent forms and withdrew because they found the study procedures to be too cumbersome.
Overall Study
STARTED
6
Overall Study
COMPLETED
0
Overall Study
NOT COMPLETED
6

Reasons for withdrawal

Reasons for withdrawal
Measure
All Participants
Participants signed the consent forms and withdrew because they found the study procedures to be too cumbersome.
Overall Study
Withdrawal by Subject
6

Baseline Characteristics

A Pilot Study on Diurnal Variation

Baseline characteristics by cohort

Baseline data not reported

PRIMARY outcome

Timeframe: Baseline and 4 weeks

Population: Participants withdrew before any data were collected.

To evaluate the patterns of change in plasma Phe and tyrosine levels between the Baseline visit and 4 week visit for each arm.

Outcome measures

Outcome data not reported

Adverse Events

PKU Participants (Arm 1)

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Control Group (Arm 2)

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Linda Randolph, M.D.

Children's Hospital Los Angeles

Phone: 323-361-2178

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place